Charles Greg Guyer Sells 5,278 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Charles Greg Guyer sold 5,278 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the sale, the executive vice president now owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioMarin Pharmaceutical Trading Down 0.4 %

Shares of BMRN traded down $0.26 on Thursday, hitting $66.40. 768,369 shares of the stock traded hands, compared to its average volume of 1,828,326. BioMarin Pharmaceutical Inc. has a 1 year low of $65.35 and a 1 year high of $99.56. The stock’s 50 day moving average is $71.24 and its two-hundred day moving average is $79.38. The firm has a market capitalization of $12.65 billion, a P/E ratio of 39.78, a P/E/G ratio of 0.65 and a beta of 0.31. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). The business had revenue of $746.00 million for the quarter, compared to analysts’ expectations of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.26 EPS. As a group, sell-side analysts predict that BioMarin Pharmaceutical Inc. will post 2.47 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Cantor Fitzgerald dropped their price objective on BioMarin Pharmaceutical from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, October 30th. StockNews.com upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Royal Bank of Canada restated a “sector perform” rating and set a $80.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 30th. Wedbush raised BioMarin Pharmaceutical to a “strong-buy” rating in a research note on Monday, November 4th. Finally, Citigroup lowered their price target on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $94.16.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in BMRN. Innealta Capital LLC acquired a new position in BioMarin Pharmaceutical in the second quarter valued at $25,000. BOKF NA acquired a new position in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $31,000. Quent Capital LLC grew its holdings in shares of BioMarin Pharmaceutical by 58.9% during the 2nd quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 145 shares during the period. nVerses Capital LLC acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in BioMarin Pharmaceutical in the second quarter valued at approximately $47,000. 98.71% of the stock is owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.